ArticleBulletin of experimental biology and medicine2025
Redox-Regulated Mechanisms of Cytotoxic Effect of Iron Nitrosyl Complex - Activator of Transcription Factor Nrf2 in Glioblastoma Cells In Vitro.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a comprehensive in vitro study of a potential antiglioma compound from the class of NO donors, a nitrosyl iron complex with N-ethylthiourea (ETM), as an activator of redox-regulated mechanisms of cellular response. The effect of ETM on glioblastoma cells is accompanied by enhanced ROS generation, accumulation of intracellular NO, a decrease in mitochondrial membrane potential, and induction of caspase-3-dependent apoptosis. The studied complex acts as an activator of Nrf2 transcription factor, and the Nrf2/HO-1-dependent pathway plays a major role in regulating redox processes triggered by this complex. Induction of this pathway does not necessarily suppress the expression of NF-κB and its target genes, but prevents activation of NF-κB-mediated mechanisms of tumor cell protection. Nrf2 activation by ETM inhibits ferroptosis in glioblastoma cells, yet does not prevent apoptotic cell death. It can be assumed that the scenario of glioblastoma cell death under the effect of Nrf2 activators is largely determined by the ability of cells to quickly reconfigure the antioxidant system under conditions of oxidative stress.
Indexed as
Identifiers
41663838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.